Drug Profile
Research programme: aptamer-based therapeutics - Archemix/GlaxoSmithKline
Latest Information Update: 19 Apr 2011
Price :
$50
*
At a glance
- Originator Archemix Corporation; GlaxoSmithKline
- Developer Archemix Corporation
- Class Oligonucleotides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 23 Dec 2008 Early research in Inflammation in USA (unspecified route)